Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

Tornero Molina, Jesús; Sanmartí Sala, Raimon; Rodríguez Valverde, Vicente; Martín Mola, Emilio; Marenco de la Fuente, José Luis; González Álvaro, Isidoro; Muñoz Fernández, Santiago; Gómez-Reino Carnota, Juan; Carreño Pérez, Luis; Batlle Gualda, Enrique; Balsa Criado, alejandro; Andreu, José Luis; Álvaro-Gracia, José María; Martínez López, Juan Antonio; Martínez López, Juan Antonio; Loza Santamaría, Estíbaliz.
Reumatol. clín. (Barc.) ; 6(1): 23-36, ene.-feb. 2010. tab
Artículo en Español | IBECS (España) | ID: ibc-78409

Documentos relacionados

  1. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis.
  2. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
  3. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
  4. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.
  5. IL-1 blockade in autoinflammatory syndromes.
  6. Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades.
  7. [IL-1 antagonists].
  8. Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever.
  9. Experience of a Single Academic Center Using IL-1 Inhibition for Rare Dermatologic Conditions.
  10. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.